# The Effects of CGM and Connected Pen in T2DM Treated With Multiple Daily Insulin Injections

Study · id `cardio:ct-nct06311019` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06311019](<https://clinicaltrials.gov/study/NCT06311019>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06311019

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 104 participants.

## Technical summary

Registry record NCT06311019. Randomized; no masking; primary purpose treatment. Start 2024-02-27 (actual); primary completion 2025-07-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT06311019, source copy `cardio:ctgov-nct06311019-2024-11-07`, retrieved 2026-10-26)
- Started: 2024-02-27 (actual) (ClinicalTrials.gov record NCT06311019, source copy `cardio:ctgov-nct06311019-2024-11-07`, retrieved 2026-10-26)
- Primary completion: 2025-07-01 (anticipated) (ClinicalTrials.gov record NCT06311019, source copy `cardio:ctgov-nct06311019-2024-11-07`, retrieved 2026-10-26)
- Completion: 2025-09-01 (anticipated) (ClinicalTrials.gov record NCT06311019, source copy `cardio:ctgov-nct06311019-2024-11-07`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT06311019, source copy `cardio:ctgov-nct06311019-2024-11-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06311019-2024-11-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of CGM and Connected Pen in T2DM Treated With Multiple Daily Insulin Injections
- Acronym: Dia2tech
- Condition: Type 2 Diabetes Treated With Insulin
- Intervention (Device): Continuous glucose monitoring and use of connected insulinpen for bolus insulin
- Lead sponsor: Klavs Würgler Hansen
- Lead sponsor class: OTHER
- Collaborator: Aarhus University Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Aarhus University Hospital (`cardio:org-aarhus-university-hospital`)

## Provenance

Content hash: 19885529f7afd0dda23dc5ed8eb46472d9116a1a4c2ed4382febf894d715037a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
